Zimmer Biomet Holdings, Inc.
Every calculator, already run for ZBH
Open the full toolkit →You have the numbers on ZBH. Get the argument.
A written report on which of these readings actually decide the outcome for Zimmer Biomet Holdings, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
27 analysts covering ZBHAnalyst Price Target Disagreement for Zimmer Biomet Holdings, Inc.
Wall Street's bull case implies +29% from the current price; the bear case implies -8%. A 37% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformiti…
ZBH — frequently asked
Is ZBH a buy right now?
Wall Street's consensus rating on Zimmer Biomet Holdings, Inc. is Buy across 27 analysts, with a mean price target of $107.57 (+7% vs. the current $100.65). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ZBH overvalued?
ZBH trades at 24.4x trailing earnings, against a DCF fair value of $222 per share. The current price implies -4% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ZBH's next earnings date?
Zimmer Biomet Holdings, Inc. is next scheduled to report earnings around Nov 5, 2026. A full ZBH research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Zimmer Biomet Holdings, Inc.?
Analysts covering Zimmer Biomet Holdings, Inc. (ZBH) range from a bear-case target of $93.00 to a bull-case high of $130.00, with a mean consensus target of $107.57 across 21 analysts. The spread of $37.00 (37% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Zimmer Biomet Holdings, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Zimmer Biomet Holdings, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ZBH research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Zimmer Biomet Holdings, Inc., in minutes. 3 free reports included with every account — no credit card required.